Arthur M. Cohen & Associates LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% in the second quarter, Holdings Channel.com reports. The firm owned 23,514 shares of the company’s stock after purchasing an additional 150 shares during the period. Johnson & Johnson comprises 1.0% of Arthur M. Cohen & Associates LLC’s portfolio, making the stock its 19th largest holding. Arthur M. Cohen & Associates LLC’s holdings in Johnson & Johnson were worth $3,307,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently modified their holdings of the company. Altshuler Shaham Ltd purchased a new position in Johnson & Johnson in the first quarter worth about $35,000. Lake Point Wealth Management increased its position in shares of Johnson & Johnson by 144.4% during the first quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock valued at $38,000 after acquiring an additional 169 shares in the last quarter. SeaBridge Investment Advisors LLC increased its position in shares of Johnson & Johnson by 160.0% during the second quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock valued at $46,000 after acquiring an additional 200 shares in the last quarter. Lion Street Advisors LLC purchased a new position in Johnson & Johnson in the 1st quarter worth approximately $45,000. Finally, Joseph P. Lucia & Associates LLC lifted its position in Johnson & Johnson by 50.8% in the 1st quarter. Joseph P. Lucia & Associates LLC now owns 374 shares of the company’s stock valued at $49,000 after acquiring an additional 126 shares in the last quarter. 68.44% of the stock is currently owned by hedge funds and other institutional investors.
In other news, EVP Ashley Mcevoy sold 29,000 shares of the company’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the sale, the executive vice president now directly owns 21,682 shares in the company, valued at approximately $3,197,444.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.27% of the company’s stock.
Shares of Johnson & Johnson stock opened at $145.76 on Friday. The firm has a market cap of $383.76 billion, a PE ratio of 21.31, a PEG ratio of 3.23 and a beta of 0.69. The stock has a 50 day moving average of $144.04 and a 200 day moving average of $144.14. The company has a current ratio of 1.25, a quick ratio of 1.05 and a debt-to-equity ratio of 0.40. Johnson & Johnson has a 12 month low of $109.16 and a 12 month high of $157.00.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Thursday, July 16th. The company reported $1.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.17. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The business had revenue of $18.34 billion for the quarter, compared to analysts’ expectations of $17.73 billion. During the same period in the prior year, the firm earned $2.58 EPS. The company’s revenue for the quarter was down 10.8% on a year-over-year basis. As a group, equities research analysts forecast that Johnson & Johnson will post 7.85 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a dividend of $1.01 per share. The ex-dividend date is Monday, August 24th. This represents a $4.04 annualized dividend and a yield of 2.77%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.54%.
JNJ has been the subject of several recent analyst reports. Independent Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price target for the stock from $161.00 to $164.00 in a research note on Monday, July 20th. UBS Group cut shares of Johnson & Johnson from a “buy” rating to a “neutral” rating and lowered their target price for the company from $163.00 to $160.00 in a research note on Tuesday, April 28th. Citigroup boosted their price objective on shares of Johnson & Johnson from $165.00 to $170.00 and gave the company a “buy” rating in a report on Friday, July 17th. Zacks Investment Research cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 target price on the stock. in a report on Tuesday, July 7th. Finally, ValuEngine lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Wednesday, July 15th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $163.38.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: Market Timing
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.